This article is more than 5 years old. Information may no longer be current.

Iluvien receives marketing authorization in Finland, Luxembourg

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg have granted Iluvien marketing authorization for the treatment of vision impairment associated with chronic diabetic macular edema, according to a press release from Alimera Sciences.

Iluvien (fluocinolone acetonide intravitreal implant) is approved for marketing in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States. It is commercially available in the United Kingdom, Germany and Portugal, the release said.

Alimera plans to commercialize Iluvien in the U.S. starting in February, the release said.